- Home
- PDO vs ELVN Comparison
PDO vs ELVN Comparison
Compare PDO & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDO | ELVN |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PDO | ELVN |
|---|---|---|
| Price | $13.32 | $50.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 594.1K | ★ 2.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.37 | $14.79 |
| 52 Week High | $14.25 | $52.39 |
Technical Indicators
Market Signals| Indicator | PDO | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 64.00 |
| Support Level | $13.16 | $25.63 |
| Resistance Level | $13.50 | $52.39 |
| Average True Range (ATR) | 0.10 | 2.66 |
| MACD | 0.03 | 0.18 |
| Stochastic Oscillator | 90.35 | 82.11 |
Price Performance
Historical ComparisonAbout PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.